Dr Reddys Laboratories Ltd (RDY) stock
RDYNYSEPharmaceutical PreparationsFiscal year ends March 31
Financials through fiscal 2026, year ended Mar 31, 2026Score 7/30
$14.74+0.01 (+0.07%)
Close on Nov 13, 2026Market cap $12.30BP/E 26.9Yield 0.58%
Dr Reddys Laboratories total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Dr Reddys Laboratories's total debt was ₹77.34B at Mar 31, 2026. For fiscal 2026 it was ₹77.34B, up 65.4% from the year before. The highest annual figure on record is ₹77.34B in fiscal 2026.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | ₹77.34B | +65.4% |
| FY2025 | Mar 31, 2025 | ₹46.77B | +133.6% |
| FY2024 | Mar 31, 2024 | ₹20.02B | +48.6% |
| FY2023 | Mar 31, 2023 | ₹13.47B | -60.2% |
| FY2022 | Mar 31, 2022 | ₹33.85B | +11.7% |
| FY2021 | Mar 31, 2021 | ₹30.30B | +37.7% |
| FY2020 | Mar 31, 2020 | ₹22.01B | -42.7% |
| FY2019 | Mar 31, 2019 | ₹38.38B | -24.2% |
| FY2018 | Mar 31, 2018 | ₹50.62B | +3.1% |
| FY2017 | Mar 31, 2017 | ₹49.10B | – |
Quarterly total debt
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | ₹77.34B | +128.5% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | ₹46.77B | +54.3% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | ₹20.02B | -9.0% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | ₹13.47B | -64.9% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | ₹33.85B | -33.1% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | ₹30.30B | -38.3% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | ₹22.01B | – |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | ₹38.38B | – |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | ₹50.62B | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | ₹49.10B | – |
See a number that looks wrong?